

    BOXED WARNING: WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

  WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS



    *  LINZESS is contraindicated in patients less than 6 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused  deaths≠B-NonOSE_AE  due to  dehydration≠B-NonOSE_AE  [see Contraindications (4), Use in Specific Populations (8.4)]. 
 *  Avoid use of LINZESS in patients 6 years to less than 18 years of age [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)]. 
 *  The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age [see Use in Specific Populations (8.4)]. 
      EXCERPT:     WARNING:  RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS  
 

   See full prescribing information for complete boxed warning.  

 *  LINZESS is contraindicated in patients less than 6 years of age; in neonatal mice, linaclotide caused deaths due to dehydration. (4, 8.4) 
 *  Avoid use of LINZESS in patients 6 years to less than 18 years of age. (5.1, 8.4) 
 *  The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age (8.4). 
    

